The clinical data are early-stage and non-pivotal, but the FDA alignment on a Phase 2 dose for WTX-124 and the safety profile in the outpatient setting are incremental positives. Monitor for initiation of Phase 2 trials and any partnership or financing updates given the $49M market cap.
Drugs in focus
HOWL drug pipeline →WTX-124
▼ Bearish Named in this 8-K- Impact
- Phase
- unknown — not confirmed this session (SecBot's FDA/ClinicalTrials.gov ingestion holds no WTX-124 records; external web s
- Time to market
- Unknown — no approval timeline exists in available sources; multi-year (if ever) from its current stage, and the program's future is clouded by the company's strategic review.
- Next catalyst
- None dated
What to watchWatch the strategic-alternatives process (no defined timeline per the July 31, 2026 Q2 update), WTX-124's fate is likely a sale/partnership or wind-down rather than a clinical binary. Also watch the cash runway: ~$22.0M at June 30, 2026 against ~$13.8M in quarterly operating expenses, with the company guiding to funding into Q2 2027. Repeated Form 144 filings from backers MPM, RA Capital and UBS Oncology and a 10.3% rise in short positions (July 15 settlement) argue against expecting a near-term squeeze.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $1.01entry
- T+1 · 7d ago −3.96%α −3.59% · $0.9700
- T+5 · 18h ago −1.90%α −0.21% · $0.9908
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Werewolf Therapeutics presented new clinical data at SITC 2026 for its two lead drug candidates, WTX-124 (IL-2 prodrug) and WTX-330 (IL-12 prodrug), in Phase 1/1b and Phase 1b/2 trials for solid tumors. The data showed safety in the outpatient setting, no vascular leak syndrome, and antitumor activity in heavily pretreated patients, including confirmed responses. The company also announced FDA alignment on a recommended Phase 2 dose of 18 mg IV Q2W for WTX-124.
Key Facts
- WTX-124 Phase 1/1b data from 155 patients showed objective responses including a durable complete response in CSCC and partial responses in melanoma and GEJ adenocarcinoma.
- WTX-124 in combination with pembrolizumab produced a 37.5% response rate in NSCLC and a 15.8% response rate in cutaneous melanoma in dose expansion.
- FDA aligned on WTX-124 recommended Phase 2 dose of 18 mg IV Q2W for monotherapy and combination with pembrolizumab.
- WTX-330 Phase 1b/2 data from 24 patients showed a confirmed partial response in gallbladder cancer and evidence of intratumoral IL-12/STAT4 signaling in 7 of 9 paired biopsies.
- Both molecules were administered safely in the outpatient setting with no vascular leak syndrome.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- Early-stage clinical data may not predict later-stage or pivotal trial results.
- The company has a small market cap ($49M) and may need additional capital to fund further development.
- No financial guidance or revenue data provided in the filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-452789 |
| Document: d169523dex991.htm | 0001193125-26-452789 |
| Document: 0001193125-26-452789-index-headers.html | 0001193125-26-452789 |
| Document: 0001193125-26-452789-index.html | 0001193125-26-452789 |
| Document: 0001193125-26-452789.txt | 0001193125-26-452789 |
Track record
31 reports on HOWL
12 of 16 bullish or bearish reports moved the stock their way by T+5. Best: +51.32% at T+60 after the Apr 27, 2026 report. 13 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.9500 Now $0.9910 +4.32% settles Nov 23
- Nov 13, 20264d ago EFFECT Neutral 4/10 Entry $0.9803 Now $0.9910 +1.09% settles Nov 20
- Nov 10, 20266d ago S-4/A Neutral 5/10 Entry $0.9889 Now $0.9910 +0.21% settles Nov 18
- Nov 9, 20267d ago 425 Neutral 5/10 Entry $0.9700 Now $0.9910 +2.16% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Viewing Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
- Oct 26, 202621d ago S-4/A Bearish 5/10 Entry $1.04 to $1.07 Now $0.9910 +4.71% ▼ −2.88% −4.87% vs SPY
- Sep 22, 20267w ago S-4 Bearish 7/10 Entry $0.9894 to $0.9223 Now $0.9910 −0.16% ▲ +6.78% +6.11% vs SPY
- Sep 21, 20268w ago SC 13G Neutral 3/10 Entry $0.9800 to $0.9300 Now $0.9910 +1.12% ▼ −5.10% −4.08% vs SPY
- Aug 21, 202612w ago 425 Bullish 7/10 Entry $0.8740 to $0.9433 Now $0.9910 +13.39% ▲ +7.93% +7.46% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers